WS #16348
Moderna stock has plummeted between 20% and 24% after third-party leaks revealed that its mRNA cancer vaccine reduced recurrence or death risk by only 42%, significantly below the 'cure' narrative that had driven retail buying. The leak occurred ahead of a major presentation at the European Society of Clinical Oncology Congress, stripping the company of its information advantage and triggering a massive sell-off. This event highlights the growing risk of data leaks in biotech and the fragility of stocks priced on binary clinical outcomes.
Biotech Data Leak
Moderna stock has plummeted between 20% and 24% after third-party leaks revealed that its mRNA cancer vaccine reduced recurrence or death risk by only 42%, significantly below the 'cure' narrative that had driven retail buying. The leak occurred ahead of a major presentation at the European Society of Clinical Oncology Congress, stripping the company of its information advantage and triggering a massive sell-off. This event highlights the growing risk of data leaks in biotech and the fragility of stocks priced on binary clinical outcomes.